ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Other: Systane
Other: Refresh Tears

First Posted Date: 2010-07-12

Last Posted Date: 2012-04-10

Lead Sponsor: Alcon Research

Target Recruit Count: 78

Registration Number: NCT01160133

Locations: 🇮🇳
Vasan Eye Care Hospital, Saidapet, Channai, India

To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure

Phase 4

Completed

Conditions: Uncontrolled Intraocular Pressure

Interventions: Drug: Travacom

First Posted Date: 2010-07-09

Last Posted Date: 2012-04-10

Lead Sponsor: Alcon Research

Target Recruit Count: 468

Registration Number: NCT01159756

Locations: 🇮🇳
Disha Eye Hospitals, Kolkata, India

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)

First Posted Date: 2010-07-09

Last Posted Date: 2012-04-03

Lead Sponsor: Alcon Research

Target Recruit Count: 215

Registration Number: NCT01159769

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Phase 2

Completed

Conditions: Exudative Age-Related Macular Degeneration

Interventions: Drug: AL-78898A
Drug: Ranibizumab

First Posted Date: 2010-07-05

Last Posted Date: 2013-06-04

Lead Sponsor: Alcon Research

Target Recruit Count: 99

Registration Number: NCT01157065

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Other: FID 115958D (Lubricant Eye Drop)

First Posted Date: 2010-06-08

Last Posted Date: 2012-02-02

Lead Sponsor: Alcon Research

Target Recruit Count: 96

Registration Number: NCT01139372

An Evaluation of a Marketed Lubricated Eye Drop in Soft Contact Lens Wearers Who Experience Ocular Dryness

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Other: FID 112903

First Posted Date: 2010-05-28

Last Posted Date: 2016-11-21

Lead Sponsor: Alcon Research

Target Recruit Count: 92

Registration Number: NCT01132287

Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

Phase 3

Completed

Conditions: Cataracts
Inflammation

Interventions: Drug: Difluprednate ophthalmic emulsion, 0.05%
Drug: Prednisolone acetate ophthalmic suspension, 1.0%

First Posted Date: 2010-05-14

Last Posted Date: 2013-06-19

Lead Sponsor: Alcon Research

Target Recruit Count: 80

Registration Number: NCT01124045

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Dexamethasone 0.1% ophthalmic suspension
Drug: Olopatadine hydrochloride 0.1% ophthalmic solution
Other: Inactive ingredients, used as placebo

First Posted Date: 2010-05-07

Last Posted Date: 2014-02-28

Lead Sponsor: Alcon Research

Target Recruit Count: 180

Registration Number: NCT01119287

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

Travoprost Five Day Posology Study

Phase 2

Completed

Conditions: Open-angle Glaucoma (OAG)
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%
Drug: Travoprost (Groups A, B and C)
Drug: Travoprost Vehicle

First Posted Date: 2010-05-03

Last Posted Date: 2011-06-23

Lead Sponsor: Alcon Research

Target Recruit Count: 60

Registration Number: NCT01114893

Locations: 🇺🇸
Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States

Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Azarga (brinzolamide 1% / timolol 0.5%)
Drug: Cosopt (dorzolamide 2% / timolol 0.5%)

First Posted Date: 2010-04-28

Last Posted Date: 2015-07-29

Lead Sponsor: Alcon Research

Target Recruit Count: 70

Registration Number: NCT01111890

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy